The protein encoded by this gene forms a potassium channel that is thought to play a critical role in the regulation of neuronal excitability, particularly in sensory cells of the cochlea. The current generated by this channel is inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. The encoded protein can form a homomultimeric potassium channel or possibly a heteromultimeric channel in association with the protein encoded by the KCNQ3 gene. Defects in this gene are a cause of nonsyndromic sensorineural deafness type 2, an autosomal dominant form of progressive hearing loss. Two transcript variants encoding different isoforms have been found for this gene.
KQT-like 4; KV7.4; Potassium channel subunit alpha KvLQT4; Potassium voltage-gated channel subfamily KQT member 4; potassium voltage-gated channel, KQT-like subfamily, member 4; potassium voltage-gated channel, subfamily Q, member 4; Voltage-gated potassium channel subunit Kv7.4